CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
Cg Oncology (CGON) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cg Oncology's actual EPS was -$0.48, missing the estimate of -$0.36 per share, resulting in a -33.19% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
